This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate ResMed (RMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ResMed Announces Complete Mobi Launch in US Markets for COPD
by Zacks Equity Research
ResMed (RMD) progresses with efforts to boost Respiratory Care suite.
ResMed Closes Propeller Health Buyout, Boosts COPD Suite
by Zacks Equity Research
ResMed (RMD) expects to boost the Respiratory Care suite with the recently-completed Propeller Health buyout.
Inogen Gains From Commercial Launch of Wireless Connect
by Zacks Equity Research
Inogen's (INGN) expanding product portfolio lends it a competitive edge in the respiratory care devices market.
ResMed to Buy Propeller Health, Widens Respiratory Care Suite
by Zacks Equity Research
Post the acquisition, Propeller will continue to operate as an independent entity within ResMed's (RMD) Respiratory Care suite.
ResMed (RMD) Closes MatrixCare Buyout, Boosts SaaS Line
by Zacks Equity Research
Post culmination of the transaction, MatrixCare will continue to operate as a standalone business within ResMed's (RMD) SaaS portfolio.
ResMed's Out-of-Hospital Line to Grow With MatrixCare Buyout
by Zacks Equity Research
MatrixCare consolidation is expected to enhance ResMed's (RMD) capacity to improve patient transitions of care as well as its provider skills.
ResMed (RMD) Looks Good: Stock Adds 5.7% in Session
by Zacks Equity Research
ResMed (RMD) shares rose nearly 6% in the last trading session, amid huge volumes.
ResMed (RMD) Q1 Earnings & Sales Beat on Overall Growth
by Zacks Equity Research
ResMed (RMD) sees solid contributions from domestic and international businesses in Q1.
ResMed (RMD) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 1.25% and 2.02%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Earnings Lineup for Oct 25: SYK, CERN & More
by Zacks Equity Research
Long-term potential of the Medical Products industry looks promising at the moment amid certain short-term geopolitical insecurities.
ResMed (RMD) Q1 Earnings Preview: What to Expect
by Zacks Equity Research
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ResMed Unveils AirFit F30, Expands AirFit Mask Portfolio
by Zacks Equity Research
ResMed's (RMD) recent product launches will strengthen its position in the high-potential sleep-disordered breathing market.
Tap the Sleep Apnea Devices Market Boom With These 3 Stocks
by Sweta Jaiswal
Consider these three stocks in the sleep apnea devices market for grand returns.
Masimo's SET Pulse Oximetry Detects Sleep Apnea in Children
by Zacks Equity Research
Masimo's (MASI) SET pulse oximetry successfully identifies DS in children with high risk of OSA.
ResMed (RMD) Q4 Earnings & Sales Beat on Overall Growth
by Zacks Equity Research
ResMed (RMD) sees solid contributions from domestic and international businesses in Q4.
ResMed (RMD) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 5.56% and 1.18%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for ResMed (RMD)
by Zacks Equity Research
ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Medical Product Earnings Lineup for Aug 2: ABC, BDX & More
by Zacks Equity Research
Strong R&D focus is likely to be the key driver of the Medical Product space in Q2.
Can Overall Growth Drive ResMed's (RMD) Q4 Earnings?
by Zacks Equity Research
ResMed (RMD) is likely to keep its winning streak alive with a gain from strong performances on the domestic as well as global front in Q4.
Boston Scientific (BSX) Q2 Earnings: Is a Beat in Store?
by Zacks Equity Research
Boston Scientific (BSX) expects to consistently gain from impressive growth across all business lines and geographies.
Will 5 Elements Drive Quest Diagnostics (DGX) Q2 Earnings?
by Zacks Equity Research
Per Quest Diagnostics (DGX), growing strength of partnerships with health care leaders and strategic acquisitions are creating growth prospects for the top and bottom-line growth.
Can Established Pharmaceuticals Up Abbott (ABT) Q2 Earnings?
by Zacks Equity Research
According to Abbott (ABT), key emerging markets represent the most attractive long-term growth opportunities for its branded generics product portfolio within EPD.
Alphabet (GOOGL) to Form JV With ResMed to Treat Sleep Apnea
by Zacks Equity Research
Alphabet's (GOOGL) Verily decides to set up a venture by joining forces with ResMed in order to reach patients with sleep apnea.
Can Abbott (ABT) Rise on Robust Overall Growth in Q2 Earnings?
by Zacks Equity Research
Abbott (ABT) gains traction from a steady healthy growth trajectory seen in core Diabetes Care business.